JP2024059648A5 - - Google Patents

Download PDF

Info

Publication number
JP2024059648A5
JP2024059648A5 JP2024014560A JP2024014560A JP2024059648A5 JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5 JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024014560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024059648A (ja
JP7760626B2 (ja
Filing date
Publication date
Priority claimed from JP2021573616A external-priority patent/JP7512310B2/ja
Application filed filed Critical
Publication of JP2024059648A publication Critical patent/JP2024059648A/ja
Publication of JP2024059648A5 publication Critical patent/JP2024059648A5/ja
Application granted granted Critical
Publication of JP7760626B2 publication Critical patent/JP7760626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024014560A 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体 Active JP7760626B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962860207P 2019-06-11 2019-06-11
US62/860,207 2019-06-11
US201962868850P 2019-06-28 2019-06-28
US62/868,850 2019-06-28
US201962874475P 2019-07-15 2019-07-15
US62/874,475 2019-07-15
US201962947503P 2019-12-12 2019-12-12
US62/947,503 2019-12-12
US202062961591P 2020-01-15 2020-01-15
US62/961,591 2020-01-15
JP2021573616A JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体
PCT/US2020/037054 WO2020252066A1 (en) 2019-06-11 2020-06-10 Anti-sortilin antibodies for use in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021573616A Division JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Publications (3)

Publication Number Publication Date
JP2024059648A JP2024059648A (ja) 2024-05-01
JP2024059648A5 true JP2024059648A5 (https=) 2025-02-28
JP7760626B2 JP7760626B2 (ja) 2025-10-27

Family

ID=71948712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体
JP2024014560A Active JP7760626B2 (ja) 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Country Status (12)

Country Link
US (2) US20200392229A1 (https=)
EP (1) EP3983441A1 (https=)
JP (2) JP7512310B2 (https=)
KR (1) KR102919581B1 (https=)
CN (1) CN114423450B (https=)
AU (1) AU2020291527A1 (https=)
BR (1) BR112021025077A2 (https=)
CA (1) CA3140023A1 (https=)
IL (1) IL288728A (https=)
MX (1) MX2021015212A (https=)
TW (1) TWI877170B (https=)
WO (1) WO2020252066A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
EP4255930A1 (en) * 2020-12-02 2023-10-11 Alector LLC Methods of use of anti-sortilin antibodies
CA3220428A1 (en) * 2021-06-08 2022-12-15 Alector Llc Methods of use of anti-sortilin antibodies
KR20250028349A (ko) 2022-06-23 2025-02-28 드라우프니르 바이오 에이피에스 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
NO2748201T3 (https=) 2011-08-23 2018-05-12
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
IL309046B2 (en) 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
LT3618928T (lt) * 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai

Similar Documents

Publication Publication Date Title
JP2022191211A5 (https=)
JP2020127044A5 (https=)
JP2025138632A5 (https=)
JP2024023385A5 (https=)
JP2024059739A5 (https=)
JP2022068302A5 (https=)
JP2020127428A5 (https=)
JP2024129139A5 (https=)
JP2025138641A5 (https=)
JP2024059648A5 (https=)
JP2023022224A5 (https=)
JP2022523200A5 (https=)
JP2021512414A5 (https=)
JP2022538797A5 (https=)
JP2024016014A5 (https=)
JP2025118629A5 (https=)
JP2024112817A5 (https=)
JP2025506484A5 (https=)
JP2023085551A5 (https=)
JP2022060295A5 (https=)
JP2025084837A5 (https=)
JP2026004279A5 (https=)
JP2024063214A5 (https=)
JP2022505647A5 (https=)
JP2024534771A5 (https=)